Industry News
Researchers explore new model of care for management of postpartum hemorrhage
1/14/2016
"A new model of care can provide policymakers with a feasible and practical way to address the prevention and treatment of postpartum hemorrhage at the community level," an international group of...
HPV vaccine uptake is highest among girls in high poverty and majority hispanic communities
1/14/2016
Adolescent girls living in high-poverty communities and majority Hispanic communities were more likely to have received at least one dose of a human papillomavirus (HPV) vaccine than those living...
Palliative care initiated in the ED associated with improved quality of life
1/14/2016
A palliative care consultation initiated in the emergency department (ED) for patients with advanced cancer was associated with improved quality of life and did not seem to shorten survival...
HPV vaccine uptake is highest among girls in high poverty and majority hispanic communities
1/14/2016
Adolescent girls living in high-poverty communities and majority Hispanic communities were more likely to have received at least one dose of a human papillomavirus (HPV) vaccine than those living...
Astellas Pharma Europe Ltd., a subsidiary of Tokyo-based Astellas Pharma Inc.
Myeloma UK opens MUK eight a clinical trial of the oral proteasome inhibitor ixazomib
1/14/2016
Myeloma UK announces that MUK eight, a Phase II trial of the oral proteasome inhibitor, ixazomib, is now open for recruitment.
Novel insights in the attachment of the bacterial carcinogen Helicobacter pylori
1/14/2016
The gastric pathogen Helicobacter pylori is highly adapted to survival in the human stomach and responsible for the majority of peptic ulcer and gastric cancer cases worldwide.
Nivolumab in melanoma: Data subsequently submitted improve assessment result
1/14/2016
The extent of added benefit increased to 'considerable' in women with BRAF V600 wt tumor, and to 'major' in men.
Long-term survivors of childhood cancer living longer thanks in part to treatment changes
1/14/2016
Evidence from the Childhood Cancer Survivor Study (CCSS) suggests that changes in childhood cancer treatment and follow-up care have reduced deaths from the late effects of cancer treatment and...
Dabrafenib/trametinib in advanced BRAF V600 mutated melanoma: Indication of added benefit
1/14/2016
Major added benefit for women due to prolongation of survival / Non-quantifiable added benefit for men.